Merck partners for ‘blockbuster’ vaccine target 26-Aug-2019 By Vassia Barba Themis obtains an exclusive licence from Merck to develop vaccine candidates with an undisclosed indication, using its measles virus vector-based platform.
Merck continues to expand oncology pipeline with $773m deal 11-Jun-2019 By Vassia Barba & Ben Hargreaves Merck acquires Tilos, a biopharmaceutical developer targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.
Merck bumps up production of MMR vaccine amid measles outbreak 08-May-2019 By Maggie Lynch With the recent outbreak of measles in the US, the only MMR vaccine producer in the US, Merck, has increased its production to meet demand.
Merck extends research agreement for NASH drug candidate 27-Mar-2019 By Maggie Lynch Merck exercises its option to extend research phase with NGM for an additional two-year period, moving the collaboration end date to March 2022.
MSD adds vaccine and biologics facility next to Keytruda site, creates 170 jobs 17-Oct-2018 By Flora Southey MSD will build a second manufacturing plant in County Carlow, Ireland, in response to growing demand.
